BLAU3
vs
B
BOVESPA
BLAU3
Over the past 12 months, BLAU3 has underperformed BOVESPA, delivering a return of +26% compared to the BOVESPA's +53% growth.
Stocks Performance
BLAU3 vs BOVESPA
Performance Gap
BLAU3 vs BOVESPA
Performance By Year
BLAU3 vs BOVESPA
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Blau Farmaceutica SA
Glance View
Blau Farmacêutica SA engages in the manufacturing of pharmaceuticals. The company is headquartered in Cotia, Sao Paulo and currently employs 1,700 full-time employees. The company went IPO on 2021-04-19. The firm focuses on the development, production and commercialization of medicines, which aim at treatment in the areas of oncology, nephrology, hematology and infectology, among others. Its product lines includes biopharmaceuticals, biosimilars, oncological - injectable, oncological - oral, blood products, antiviral and antiretrovirals, uterine stimulators, anaesthetics, antithrombotics, thrombolytics, female health care, antibiotics, non-beta lactams, cephalosporin, chloramphenicol, acid pumper inhibitor and other hospital products. The firm operates in Brazil, Argentina, Colombia, Peru, Uruguay, Chile and the United States, having a pharmaceutical industrial complex composed of five industrial plants, dedicated to the production of biological, biotechnological and oncological medicines, antibiotics, injectable anesthetics and biotechnological inputs.
